FGF-2 Polyclonal Antibody
¥680.00
FA8A (heavy chain 92k, Cleaved-Arg759) rabbit pAb
活动价：
¥680.00
市场价：¥880.00
一键复制产品信息
产品规格：
- 50μL
- 100μL
货号：
FAB2600152
- 产品信息
商品描述
靶点-Target
FA8A
反应性
Human,Mouse
应用
WB,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Unmodified
MW(Observed)
92kD,260kD
推荐稀释比
WB 1:1000-2000;ELISA 1:5000-20000
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
Synthesized peptide derived from human FA8A (heavy chain 92k, Cleaved-Arg759)
特异性
This antibody detects endogenous levels of Human,Mouse FA8A (heavy chain 92k, Cleaved-Arg759, protein was cleaved amino acid sequence between 759-760 )
基因名称
F8 F8C
蛋白名称
FA8A (heavy chain 92k, Cleaved-Arg759)
别名
Coagulation factor VIII;Antihemophilic factor;AHF;Procoagulant component;[Cleaved into: Factor VIIIa heavy chain, 200 kDa isoform;Factor VIIIa heavy chain, 92 kDa isoform;Factor VIII B chain;Factor VIIIa light chain]
Organism-1
Human
基因ID-1
2157
SwissProt-1
P00451
Organism-2
Mouse
基因ID-2
14069
SwissProt-2
Q06194
背景
disease:Defects in F8 are the cause of hemophilia A (HEMA) [MIM:306700]. HEMA is a common recessive X-linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is non-functional; i.e., the F8C activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.,domain:Domain F5/8 type C 2 is responsible for phospholipid-binding and essential for factor VIII activity.,function:Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.,mass spectrometry:Disulfated PubMed:10368977,mass spectrometry:Monosulfated PubMed:10368977,mass spectrometry:Nonsulfated PubMed:10368977,mass spectrometry:Sulfated PubMed:10368977,mass spectrometry:Trisulfated PubMed:10368977,online information:Factor VIII entry,online information:Factor VIII mutation db,pharmaceutical:Available under the names Kogenate (Bayer) and Recombinate (Baxter and American Home Products). Used to treat hemophilia A.,PTM:Sulfation on Tyr-1699 is essential for binding vWF.,similarity:Belongs to the multicopper oxidase family.,similarity:Contains 1 F5/8 type C domain.,similarity:Contains 2 F5/8 type C domains.,similarity:Contains 3 F5/8 type A domains.,similarity:Contains 6 plastocyanin-like domains.,subunit:Interacts with vWF. vWF binding is essential for the stabilization of F8 in circulation.,
细胞定位
Secreted, extracellular space.
